

Human Blood-Derived Raw Material: Enabling Controlled, Consistent Collection

Thomas V. Ramos, MS, MBA, William F. Busby, III, Gaytha McPherson • HemaCare BioResearch Products • (877) 397-3087 • tramos@hemacare.com
Scott R. Burger, MD • Advanced Cell & Gene Therapy, LLC • (919) 969-1103 • celltherapy@ac-gt.com



HemaCare
BioResearch Products
Your Research • Our Cells • Your Way

Abstract

Human cells are critical raw materials for manufacturing cell therapy products, but often introduce significant variability. Rigorous operational controls and quality systems, however, enable optimal collection of high-quality, consistent cellular material. HemaCare, a long-standing supplier of human-derived blood components, controls apheresis procedures and collection sites under a formal quality system, with GMP-compliant, validated procedures and equipment, and GTP-compliant donor screening and tracking.

HemaCare performed 69,658 cellular apheresis collections in the last five years, including patient and normal-donor PBMCs, G-CSF-mobilized PBPCs and plateletpheresis products, for research, clinical trials, and commercial products.

Expanded capabilities include disease-state and normal-donor bone marrow, umbilical cord blood, and cord tissue collection, immunomagnetic cell selection, cryopreservation, and analysis by flow cytometry.

HemaCare unmobilized apheresis products showed consistently high MNC purity, with 93.8% of products containing $\geq 75\%$ MNC, and an average of $85.2\% \text{ MNC} \pm 6.6\%$ (mean $\pm 1 \text{ SD}$).

Red blood cell contamination was low, with hematocrit averaging $1.8\% \pm 0.8\%$.


Approximately 85% of HemaCare donors have donated apheresis products 5 or more times, and this repeat-donor pool also contributes to product consistency, as MNC content of individual donor apheresis products had an average coefficient of variation of 3.5%, compared to a CV of 7.7% for all apheresis products.

1

About HemaCare BioResearch Products

HemaCare is a leading provider of apheresis products, human blood cells, apheresis collection services, and therapeutic apheresis services

- Apheresis collections and blood-derived products for preclinical research, clinical studies from Phase I to Phase IV, and commercial applications
- Supports applications in immunotherapy, cell therapy, assay development, and medical devices
 - Apheresis PBMC
 - G-CSF-mobilized PBSC
 - Bone marrow
 - Cord blood
 - Peripheral blood
 - Plasma, serum
 - Cell subpopulations
 - CD34⁺
 - CD3⁺, CD4⁺, CD8⁺
 - CD19⁺, CD56⁺, others
 - Healthy-donor and disease-state products
 - Fresh and cryopreserved products



2

The HemaCare Advantage

HemaCare is committed to providing our customers with experienced, personalized, responsive, cost effective, and value added services.

Research Products and Cellular Therapy Services


- Donor pool is already pedigreed and will continue to be expanded
- Extensive donor registry with ability to request repeat donor collections
- Predictable, reliable, and validated collection procedures
- Optimized Standard Operating Procedures leading to high degree of standardization and control
- Ability to collect based on specific, customizable protocols
- High-yield, consistent cell collections
- Validated, automated cell counts and five-part WBC differentials
- Established distribution redundancies leading to the ability to ship via FedEx, UPS, World Courier, and various local couriers
- Access to our scientific/technical support 24/7/365

3

Human Cells: Standardizing Living Biological Raw Material Through Quality Processes

- Human blood-derived cells are critical raw material for cell therapy, tissue-engineered products, and ex vivo gene therapy products
- Quality and consistency of cellular raw material is a major determinant of final product characteristics
- Controlling cell collection minimizes variability and increases likelihood of success in research and manufacturing
- Training and experience are critical
- Quality systems standardize and control operations


Controlled collection procedures yield optimal, consistent products



4


Quality Indicators

- Tracking and trending
 - Donor reactions, deviations, exceptions, suppliers, risks, equipment performance, etc...
- Product QC analysis
 - Automated cell counter/analyzer, 5-part WBC differential (Horiba Pentra analyzer)
 - Nucleated cell (WBC) content and subpopulations, mononuclear cell %, HCT, product volume, etc...
- Donor Testing
 - Screening, Infectious disease testing, CBC with 5-part WBC differential
- Internal and external audits



5

Selected Apheresis Product Quality Indicators MNC Purity/Content, RBC Contamination



MNC Purity
Mean $85.2\% \pm 6.6\%$ (mean $\pm 1 \text{ SD}$)
93.8% of products $\geq 75\%$ MNC


MNC Content
 $10.6 \pm 3.8 \times 10^9$ (mean $\pm 1 \text{ SD}$)

RBC Contamination
Hematocrit $1.8\% \pm 0.8\%$ (mean $\pm 1 \text{ SD}$)
91.3% of products $\leq 2.5\%$ hematocrit

6

Donors – The Critical Source


- All donors are qualified per regulations and protocol requirement, with IRB-approved informed consent
- Pedigreed, well-characterized apheresis donor population
 - 85% of HemaCare donors have donated ≥ 5 times/year
 - Facilitates recruitment of donors with specific characteristics required by investigator
 - Medical history, HLA type, other laboratory test results, age, gender, ethnicity, etc...
 - Repeat donors further minimize variability



- Mean 3.5% CV for products per donor
- Mean 7.7% CV for all products
- n=21 donors, 3-5 products/donor

7

External Quality Indicators Dendreon Supplier Scorecard



8

External Quality Indicators

100%
Right First Time Award

This is awarded to:
HemaCare Blood Donor Center
For its commitment to 100% correct collections


Year Awarded : 2011



9

Non-Cryopreserved PBMC Storage


- For many applications, PBMC apheresis products must be used or cryopreserved within 24-48 hours post-collection. Storage in HypoThermosol® (BioLife Solutions) has been shown to increase stability of a variety of cell types, and could extend shelf-life of apheresis PBMCs.
- HemaCare has begun testing stability of MNCs and cell subpopulations stored in HypoThermosol for up to 96 hr without cryopreservation.



Test at t = 0, 24 hr, 48 hr, 96 hr
Cell count with differential
Total WBC and MNC content
% Viable cells (7-AAD)
% Viable MNC recovery
Viable CD4⁺, CD8⁺, CD14⁺, CD19⁺ cell frequency

10

Non-Cryopreserved PBMC Storage Pilot Data



11

Summary

- Collecting blood-based cellular products in a manner that minimizes variability brings a higher degree of reproducibility to the research project or manufacturing effort
- Quality-based controls such as standardized SOPs, staff training and competency assessments, equipment management, and monitoring of quality indicators reduce this variability
- Availability of repeat donors from a pedigreed donor base enhances the quality and value of this critical, living biological material
- Use of cGMP, serum-free, protein-free biopreservation media such as HypoThermosol shows great promise to enable worldwide shipment of fresh cellular products isolated from apheresis collection, extending shelf-life of cell therapy products, and delaying need for cryopreservation

12